Pegylated interferon-alpha-2a

Pegylated interferon alfa-2a (40kD) (commercial name PEGASYS) is an antiviral drug discovered at the pharmaceutical company F.Hoffmann-La Roche; it has a dual mode of action – both antiviral and on the immune system.

This drug is approved around the world for the treatment of chronic hepatitis C (including patients with HIV co-infection, cirrhosis, ‘normal’ levels of ALT) and has recently been approved (in the EU, U.S., China and many other countries) for the treatment of chronic hepatitis B.

• Interferon
• PEGylation

• PMPRB at pmprb-cepmb.gc.ca
• Pegasys at the US National Library of Medicine Medical Subject Headings (MeSH)

de:Peginterferon α

Template:WikiDoc Sources